Related Experiment Video
Updated: Aug 4, 2026
07:50
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
Published on: July 16, 2012
Non-steroidal anti-inflammatory drugs in everyday practice
1Department of Rheumatology and Physiotherapy, Flór Ferenc Hospital Pest County, Kerepestarcsa, Hungary.
Therapia Hungarica (English Edition)
|January 1, 1994
Summary
Non-steroidal anti-inflammatory drug (NSAID) therapies present significant clinical challenges due to variable patient responses and toxicity. Careful drug selection and judicious use are crucial, especially in the elderly, as continuous NSAID treatment is often unnecessary.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Therapy
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
- Their clinical effectiveness and toxicity profiles vary significantly among different agents.
- Patient responses and adverse effects exhibit considerable individual variability.
Purpose of the Study:
- To review the theoretical and practical issues surrounding NSAID therapies.
- To highlight recent findings explaining variations in NSAID efficacy and toxicity.
- To emphasize risks associated with NSAID use, particularly in the elderly population.
Main Methods:
- Literature review of existing references on NSAID therapies.
- Analysis of recent observations on NSAID clinical effectiveness and toxicity.
- Examination of factors contributing to individual patient responses and adverse events.
Main Results:
- NSAID effectiveness and toxicity differ based on the specific drug and individual patient factors.
- Elderly patients face increased risks when using NSAIDs.
- Significant variations exist in how patients respond to NSAIDs, leading to diverse outcomes.
Conclusions:
- Proper selection of NSAIDs is critical for optimizing therapeutic outcomes and minimizing adverse effects.
- Continuous use of NSAIDs is not required for a large number of patients.
- A more individualized approach to NSAID therapy is warranted, considering patient-specific factors and risk profiles.
More Related Videos
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...